

Briefing on HIV Post-exposure Prophylaxis (Revised May 2009)

DH Guidance published in September 2008

The London HIV Drugs & Treatment Sub-Group recently discussed the arrangements for providing HIV post-exposure prophylaxis across London, taking into account the *Guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS* published in September 2008. The following actions were agreed:

- The standard regimen will be one Truvada (245mg tenofovir and 200mg emtricitabine) plus two Kaletra film-coated tablets (200mg lopinavir and 50mg ritonavir) twice a day.
- The maximum course of treatment will be 30 days.
- There will be a standard 5-days starter pack containing the antiretroviral drugs and a supply of domperidone and loperamide to treat nausea and diarrhoea side effects. The pack will also contain a detailed patient information leaflet which will be produced in collaboration with patient representative groups. An NHS Trust pre-packing unit will be commissioned to provide the starter pack for all London NHS Trusts at a standard cost. The packs will generally be issued to patients by Accident and Emergency departments, although other departments may be designated locally.
- Follow-up continuation treatment, up to a maximum of 25 days' supply, will be prescribed by HIV/GUM departments in accordance with local policy.
- These arrangements will cover both PEP and PEPSE patients **although only treatment for PEPSE patients may be reclaimed from PCTs.**

Annual Patient Numbers

To date, an annual demand for 2,396 PEP/PEPSE starter packs has been identified from 15 NHS Trusts. It is anticipated that total demand will be between 3,000 and 3,500 packs (see table in Appendix 1). At this stage, it has not been possible to separate occupational PEP from PEPSE use.

Financial Implications

The full cost of one course of treatment is **£631.50**. This price includes VAT at the current rate of 15.0% but there may be a price increase in January 2010 when the Government reviews the VAT rate.

Based on the anticipated annual demand for 3,000 to 3,500 packs, the total annual cost for PEP/PEPSE in 2009/10 will be **£1.83m to £2.14m**. Assuming that 70% of usage relates to PEPSE, the total cost that might be funded through a PCT tariff would be **£1.28m to £1.50m**. (Note: the actual split between PEP and PEPSE use is not known.)

PEP and PEPSE Funding

In the past, the HIV Consortium has informed providers that both PEP and PEPSE drug costs should not be charged to local HIV drug budgets. The assumption has been made that trusts comply with this

requirement and that the costs are borne either from another trust budget for PEP or through PCT recharging for PEPSE. It is otherwise extremely difficult to monitor this expenditure against total annual drug expenditure on antiretroviral drugs of £140m. However, it may be that a more effective monitoring system could be put in place both to ensure that charging to the HIV budget does not occur and that a full audit trail for charging PEPSE to the PCTs can be established.

The following is a copy of the monitoring form used by St. Mary's Hospital. No doubt there are similar arrangements in other trusts. It should be possible to introduce a standardised data collection form and process in all trusts, possibly by April 2009. This should allow for greater distinction between occupational PEP and PEPSE patients, identification of patients' PCTs and appropriate recharging to PCTs against the PEPSE tariff.

Pharmacy Department
St. Mary's Hospital
Praed Street
Paddington
London
W2 1NY

Prescription for HIV Post Exposure Prophylaxis (PEP)

Please issue full pack- do not remove items or supply part packs

Date: ___/___/___

Name of exposed person _____
Hospital/ A&E no: _____
DOB: _____
Postcode _____
Staff member / non staff (please circle)

- Please Supply:
- *Combivir 1 tablet b.d. for 4 days (8 tablets)*
 - *Kaletra 2 tablets b.d. for 4 days (16 tablets)*
 - *Domperidone 10mg t.d.s as required (30 tablets)*
 - *Loperamide (30 tablets)*

Prescriber's signature _____

Please ensure each recipient receives the information leaflets included in the starter pack

- Combivir
- Kaletra
- Information On Post Exposure Prophylaxis (PEP) Following Exposure To HIV

Please **return the completed prescription** in an internal envelope marked confidential to:
Rosy Weston, Pharmacy Team leader HIV and Sexual Health, Jefferiss Wing,
Department of HIV/ GUM or fax to ext. 1575
August 2008

PEP/PEPSE Pack Requirements

Trust/Centre	Projected annual usage of PEP/PEPSE packs
Barking, Havering & Redbridge	
Barts & The London	360
Bromley	
Camden (Whitt and UCLH)	200
C&W/Charing Cross	
Ealing	30
Epsom & St. Helier	
Guys & St.Thomas'	400
Hillingdon	40
Homerton	
Imperial	500
Kings College	220
Kingston	60
Lewisham	80
Mayday	80
Newham	120
North Middlesex	
NW London Hosps	106
Queen Elizabeth	50
Royal Free	150
St George's	
West Middlesex	
Whipps Cross	
Totals	2396

Peter Sharott

Pharmaceutical Adviser, London Specialised Commissioning Group

December 2008 (updated May 2009)